A Non-interventional Observational Study Evaluating Treatment Patterns and Safety of Avacincaptad Pegol in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

What this Trial Is About

This research focuses on people with geographic atrophy caused by age-related macular degeneration AMD. AMD damages the macula, the light-sensitive part of the retina, leading to worsening central vision. Geographic atrophy is an advanced form where retinal cells waste away, potentially causing permanent vision loss. The study observes how patients with this condition are treated in regular medical practice, especially those receiving avacincaptad pegol, a US-approved treatment for geographic atrophy. Participants in this observational study have already decided with their doctors to begin treatment with avacincaptad pegol via intravitreal injection. The study does not assign treatment but collects information on how this drug is used, monitoring patients over time. This includes tracking treatment patterns, safety, and any medical problems linked to avacincaptad pegol. The study runs for about five years, recording ongoing care and treatment decisions. During the study, participants will have routine eye exams and complete surveys about their eye health. Surveys occur at treatment start, every six months for two years, then annually. Researchers will gather data from medical records on the number and frequency of injections, treatment duration, reasons for stopping treatment, and patient characteristics. They will also monitor vision changes and adverse events. This long-term follow-up helps understand real-world use and safety of avacincaptad pegol in geographic atrophy care.

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy